Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 24 results.
User Information
Export Records
  1. 1.   A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
  2. Azad, N.; Perroy, A.; Gardner, E.; Imamura, C. K.; Graves, C.; Sarosy, G. A.; Minasian, L.; Kotz, H.; Raggio, M.; Figg, W. D.; Kohn, E. C.
  3. Cancer Biology & Therapy. 2009 8(19): 1800-1805.
  1. 2.   Connecting chemosensitivity, gene expression and disease
  2. Covell, D. G.
  3. Trends in Pharmacological Sciences. 2008 29(1): 1-5.
  1. 3.   Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data
  2. Covell, D. G.; Huang, R. L.; Wallqvist, A.
  3. Molecular Cancer Therapeutics. 2007, Aug; 6(8): 2261-2270.
  1. 4.   The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells
  2. Mi, L. X.; Wang, X. T.; Govind, S.; Hood, B. L.; Veenstra, T. D.; Conrads, T. P.; Saha, D. T.; Goldman, R.; Chung, F. L.
  3. Cancer Research. 2007, Jul; 67(13): 6409-6416.
  1. 5.   Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells
  2. Lou, J. R.; Fatima, N.; Xiao, Z.; Stauffer, S.; Smythers, G.; Greenwald, P.; Ali, I. U.
  3. Cancer Epidemiology Biomarkers & Prevention. 2006, Sep; 15(9): 1598-1606.
  1. 6.   Evidence that sequence homologous region in LRAT-like proteins possesses anti-proliferative activity and DNA binding properties: translational implications and mechanism of action
  2. Simmons, D. P.; Peach, M. L.; Friedman, J. R.; Green, M. M. B.; Nicklaus, M. C.; De Luca, L. M.
  3. Carcinogenesis. 2006, Apr; 27(4): 693-707.
  1. 7.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 8.   New arylthioindoles: Potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies
  2. De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R.
  3. Journal of Medicinal Chemistry. 2006, FEB 9; 49(3): 947-954.
  1. 9.   Evaluating chemical structure similarity as an indicator of cellular growth inhibition
  2. Wallqvist, A.; Huang, R. L.; Thanki, N.; Covell, D. G.
  3. Journal of Chemical Information and Modeling. 2006, JAN-FEB; 46(1): 430-437.
  1. 10.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huan, R.; Wallqvist, A.; Thanki, N.; Covell, D.
  3. Clinical Cancer Research. 2005, DEC 15; 11(24, Part 2 Suppl. S): 9069S-9069S.
  1. 11.   Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients
  2. Shebzukhov, Y. V.; Koroleva, E. P.; Khlgatian, S. V.; Belousov, P. V.; Kuz'mina, K. E.; Radko, B. V.; Longpre, F.; Lagarkova, M. A.; Kadachigova, T. S.; Gurova, O. V.; Meshcheryakov, A. A.; Lichinitser, M. R.; Knuth, A.; Jager, E.; Kuprash, D. V.; Nedospasov, S. A.
  3. International Journal of Cancer. 2005, DEC 10; 117(5): 800-806.
  1. 12.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 13.   Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O-6-benzylguanine
  2. Fishel, M. L.; Ganicsik, M. P.; Delaney, S. M.; Zuhowski, E. G.; Maher, V. M.; Karrison, T.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2005, APR; 55(4): 333-342.
  1. 14.   Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action
  2. Huang, R.; Wallqvist, A.; Thanki, N.; Covell, D. G.
  3. Pharmacogenomics Journal. 2005 5(6): 381-399.
  1. 15.   Secondary metabolites of Phlomis viscosa and their biological activities
  2. Calis, I.; Kirmizibekmez, H.; Beutler, J. A.; Donmez, A. A.; Yalcin, F. N.; Kilic, E.; Ozalp, M.; Ruedi, P.; Tasdemir, D.
  3. Turkish Journal of Chemistry. 2005 29(1): 71-81.
  1. 16.   Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells
  2. Liang, H. Y.; Salinas, R. A.; Leal, B. Z.; Kosakowska-Cholody, T.; Michejda, C. J.; Waters, S. J.; Herman, T. S.; Woynarowski, J. M.; Woynarowska, B. A.
  3. Molecular Cancer Therapeutics. 2004, NOV; 3(11): 1385-1396.
  1. 17.   Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts
  2. Rapisarda, A.; Zalek, J.; Hollingshead, M.; Braunschweig, T.; Uranchimeg, B.; Bonomi, C. A.; Borgel, S. D.; Carter, J. P.; Hewitt, S. M.; Shoemaker, R. H.; Melillo, G.
  3. Cancer Research. 2004, OCT 1; 64(19): 6845-6848.
  1. 18.   Preferential response of cancer cells to zebularine
  2. Cheng, J. C.; Yoo, C. B.; Weisenberger, D. J.; Chuang, J.; Wozniak, C.; Liang, G. N.; Marquez, V. E.; Greer, S.; Orntoft, T. F.; Thykjaer, T.; Jones, P. A.
  3. Cancer Cell. 2004, AUG; 6(2): 151-158.
  1. 19.   Transcriptional coregulator SNURF (RNF4) possesses ubiquitin E3 ligase activity
  2. Hakli, M.; Lorick, K. L.; Weissman, A. M.; Janne, O. A.; Palvimo, J. J.
  3. Febs Letters. 2004 560(1-3): 56-62.
  1. 20.   Sensitivity of renal cell carcinoma to aminoflavone: Role of CYP1A1
  2. Loaiza-Perez, A. I.; Kenney, S.; Boswell, J.; Hollingshead, M.; Hose, C.; Linehan, W. M.; Worrell, R.; Rubinstein, L.; Sausville, A.; Vistica, D. T.
  3. Journal of Urology. 2004 171(4): 1688-1697.
  1. 21.   Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins - A molecular link of two tumor suppressor pathways
  2. Birchenall-Roberts, M. C.; Fu, T.; Bang, O. S.; Dambach, M.; Resau, J. H.; Sadowski, C. L.; Bertolette, D. C.; Lee, H. J.; Kim, S. J.; Ruscetti, F. W.
  3. Journal of Biological Chemistry. 2004 279(24): 25605-25613.
  1. 22.   CD27 signals through PKC in human B cell lymphomas
  2. Erlichman, B.; Howard, O. M. Z.
  3. Cytokine. 1999 11(7): 476-484.
  1. 23.   Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric Cll-1 Monoclonal Antibodies Against Various Human Lymphoma Cell Lines in Vitro and in Vivo
  2. Funakoshi, S.; Hirano, A.; Beckwith, M.; Asai, O.; Jorgensen, G.; Tian, Z. G.; Hornick, J. L.; Hu, P. S.; Khawli, L. A.; Epstein, A. L.; Longo, D. L.; Murphy, W. J.
  3. Blood. 1997 90(8): 3160-3166.
  1. 24.   Effects of Cd40 Stimulation in the Prevention of Human Ebv-Lymphomagenesis
  2. Funakoshi, S.; Taub, D. D.; Asai, O.; Hirano, A.; Ruscetti, F. W.; Longo, D. L.; Murphy, W. J.
  3. Leukemia & Lymphoma. 1997 24(3-4): 187 ff..
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel